• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Indivior Pharmaceuticals, Inc. - Common Stock (NQ:INDV)

    36.37 -1.00 (-2.68%)
    Streaming Delayed Price Updated: 2:37 PM EDT, Aug 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Indivior Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    Halper Sadeh LLC is Investigating Whether LNTH, ATKR, INDV are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
    From Supernus Pharmaceuticals, Inc.; Indivior Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior to Participate in Upcoming Investor Conferences
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior Announces $175 Million Accelerated Share Repurchase
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior Announces Proposed Convertible Senior Notes Offering
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior to Participate in Upcoming Investor Conferences
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior Announces Completion of Redomiciliation to the United States
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior Provides Full-Year 2026 Financial Guidance and Business Update
    From Indivior Inc.
    Via GlobeNewswire
    News headline image
    INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Indivior PLC (INDV)
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    INDV Deadline: Rosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Indivior, CrowdStrike, DXC, and Five Below and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    ROSEN, A LEADING LAW FIRM, Encourages Indivior PLC Investors to Secure Counsel Before Important October 1 Deadline in Securities Class Action – INDV
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    INDIVIOR PLC (NASDAQ: INDV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Indivior PLC Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Indivior, CrowdStrike, DXC, and Five Below and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Indivior PLC REMINDER – INDV Stockholders Should Contact Robbins LLP for Information About the Indivior PLC Class Action and Pending Lead Plaintiff Deadline
    From Robbins LLP
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.